Negin Salimi, DO
Hospice and Palliative Medicine · San Diego, CANPI 1326215815
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AstraZeneca at 44.9% of the total.
Across 22 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$215
- Eisai Inc.$43
- Amgen$24
- Daiichi Sankyo Inc.$24
- Bristol Myers Squibb$23
- AMAG Pharmaceuticals, Inc.$21
- plus $129 from 8 others
What the payments were for
- Food & beverage$45696%
- Education$214%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $215 |
| Eisai Inc. | 2 | $43 |
| Amgen | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $23 |
| AMAG Pharmaceuticals, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Incyte Corporation | 1 | $20 |
| Johnson & Johnson | 1 | $17 |
| EMD Serono, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Advanced Accelerator Applications | 1 | $13 |
| Merck | 1 | $12 |
How this compares
$478 in reported general payments places this provider in the 80th percentile of 195 hospice and palliative medicine providers in California.
See all hospice and palliative medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 18 | $7,894 |
| MovantikNaloxegol Oxalate | 14 | $5,789 |
| Oxycodone Hcl | 98 | $2,292 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 46 | $1,657 |
| Methadone Hcl | 68 | $1,127 |
| Naloxone Hcl | 17 | $1,034 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 30 | $895 |
| Lidocaine | 11 | $714 |
| Gabapentin | 28 | $492 |
| Pregabalin | 18 | $440 |
| Hydromorphone Hcl | 21 | $371 |
| Mirtazapine | 28 | $367 |
| Morphine Sulfate ErMorphine Sulfate | 17 | $342 |
| Duloxetine Hcl | 19 | $331 |
| Morphine Sulfate | 18 | $304 |
Paid to pharmacies, not to this prescriber.
Other hospice and palliative medicine in San Diego
- David WangSan Diego$303
- Michelle QuanSan Diego$258
- Sharon YeeArcadia$44K
- Neil SoniFountain Valley$28K
- Marietta Abalos-GalitoSan Jose$21K
- Humayon KhanSanta Ana$7K
- Sorin BugaDuarte$5K
- Glenn CarrFresno$5K
- Steven HarrisFoster City$5K
- Christopher PhillipsMurrieta$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.